Intelligence

Analysis

When two cytometry laboratories agree: what 73 paired T-cell measurements really prove

A paired FACSCanto II comparison found close agreement in CD3, CD4 and CD8 percentages—but its practical lesson is controlled transfer, not universal laboratory equivalence.

Technical Review of Aziz et al., Laboratory Medicine 56:271–278 (2025), DOI 10.1093/labmed/lmae091. Peer-reviewed paired laboratory method-comparison study; not a general instrument validation.

The hidden risk when a long-running cohort changes laboratories

A longitudinal study can mistake an analytical transition for a biological trend. Aziz and colleagues evaluated this risk when basic T-cell phenotyping could move from a research facility to a diagnostic laboratory. Seventy-three EDTA blood specimens from male cohort participants were tested by both laboratories, including 47 participants living with HIV-1 and 26 without HIV-1. Both sites used FACSCanto II instruments and matched methods. The immediate question was whether changes in CD3, CD4 or CD8 percentages would make the cohort's past and future data incomparable.

What the paired data showed

Using Bland–Altman comparisons, the authors reported 69 of 73 CD3, 71 of 73 CD4 and 72 of 73 CD8 paired percentage results within their calculated limits of agreement. Mean laboratory differences were −1.000, −0.945 and +0.685 percentage points, respectively, for CD3, CD4 and CD8. These refer to relative T-cell measurements, not demonstrated agreement for absolute counts, rare populations or all lymphocyte subsets. Four CD3 pairs, two CD4 pairs and one CD8 pair exceeded the reported statistical limits.

The study also compared paired differences with a prespecified local tolerance of ±5 percentage points, chosen with reference to the quality context of the longitudinal laboratory. Such a criterion must not be copied uncritically into an unrelated clinical validation: acceptable error depends on measurand, concentration, intended use and applicable performance standards.

How the transfer was controlled

Instrumentation alone was not the entire measurement chain. The paper discusses preanalytical specimen handling, anticoagulant, staining, reagent consistency, acquisition, gating and postanalytical checks. The results support method continuity under these closely matched conditions. They do not demonstrate equivalent performance between different cytometer families, laboratory-specific SOPs, antibody clones or sample transport conditions.

Original CFCM schematic separating matched methods and sample transfer, paired percentage agreement, and the boundaries of clinical generalisation.
Original CFCM conceptual diagram. Educational synthesis; not clinical validation.

What a clinical laboratory should actually take from this

Before changing site, assess paired data across relevant clinical ranges, not just a pooled correlation. Review systematic differences and limits of agreement, document acceptance criteria before analysis, and include day-to-day QC and difficult specimens. If reporting absolute CD4 counts, study their full counting method separately; percentages cannot substitute for count verification. Track assay version and site in longitudinal records so a future discontinuity remains interpretable.

Limits that matter

This was a specific cohort-based comparison of basic T-cell percentages with one instrument family and a restricted participant population. It is evidence about those paired methods, not an external validation of diagnostic interchangeability, MRD sensitivity, or all ethnic and disease groups. The article's practical strength is the disciplined question it asks about continuity.

Daily Learning Pill

Interlaboratory agreement is a property of the complete method, the measurand and its intended use—not a universal property of a shared cytometer model.

Primary full text: Aziz et al., Laboratory Medicine. Related practical resources: CFCM Troubleshooting. The figure above is original CFCM educational synthesis; no source figure is reproduced.